Fig. 1.

Cumulative incidence of diabetes, stratified by treatment group, for the four-arm Diabetes Prevention Program, including the troglitazone treatment group (N = 2,343). Troglitazone (TROG) versus placebo (PLAC), P<0.001; troglitazone versus metformin (MET), P = 0.02; troglitazone versus intensive lifestyle (ILS), P = 0.18. Adapted from Knowler et al (Diabetes Prevention Program Research Group) (6).